ClinicalTrials.Veeva
Menu

Find clinical trials for Lymphoma in Sevilla, AN

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

B-Cell Lymphoma
Non-Hodgkin Lymphoma
Diffuse Large B-Cell Lymphoma
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia
B-Cell Chronic Lymphocytic Leukemia
Follicular Lymphoma

Lymphoma trials near Sevilla, AN, ESP:

A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma (RELATIVITY-069)

and preliminary efficacy of relatlimab plus nivolumab in pediatric and young adult participants with recurrent or refractory classical Hodgkin lymphoma...

Enrolling
Lymphoma, Non-Hodgkin
Hodgkin Disease
Drug: Relatlimab
Drug: Nivolumab

Phase 1, Phase 2

Bristol-Myers Squibb (BMS)
Bristol-Myers Squibb (BMS)

Seville, Spain and 76 other locations

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma...

Active, not recruiting
Relapsed/Refractory Peripheral T-Cell Lymphoma
Adult T Cell Leukemia/Lymphoma
Drug: Valemetostat Tosylate

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Seville, Spain and 59 other locations

dose of BGB-11417 monotherapy for relapsed or refractory mantle cell lymphoma. Part 2 evaluates efficacy of BGB-11417 monotherapy at the rec...

Active, not recruiting
Mantle Cell Lymphoma
Relapsed Mantle Cell Lymphoma
Drug: BGB-11417

Phase 1, Phase 2

BeiGene
BeiGene

Seville, Spain and 104 other locations

on participants who have one of two types of cancer: follicular lymphoma (FL) or marginal zone lymphoma (MZL) that has come back af...

Enrolling
Relapsed/Refractory Follicular Lymphoma
Relapsed/Refractory Marginal Zone Lymphoma (R/R MZL)
Drug: Lenalidomide
Drug: Odronextamab

Phase 3

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Seville, Spain and 167 other locations

Single-arm, open-label, multicenter, phase II trial aiming to include approximately 45 patients over 24 months. Patients will receive axicabtagene ci...

Enrolling
DIFFUSE LARGE B-CELL LYMPHOMA
Drug: Axicabtagene Ciloleucel

Phase 2

Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Seville, Sevilla, Spain and 14 other locations

duvelisib monotherapy as compared to investigator's choice of gemcitabine or bendamustine in participants with relapsed/refractory nodal T cell lymphoma...

Enrolling
Lymphoma
Drug: Duvelisib
Drug: Bendamustine

Phase 3

Secura Bio
Secura Bio

Seville, Spain and 42 other locations

This is a global Phase 2, open-label, single-arm, multicohort, multicenter study to evaluate efficacy and safety of JCAR017 in adult subjects with r/...

Active, not recruiting
Lymphoma, Non-Hodgkin
Drug: Fludarabine
Drug: JCAR017

Phase 2

Celgene
Celgene

Seville, Spain and 48 other locations

The purpose of this study is to evaluate the efficacy of loncastuximab tesirine (ADCT-402) combined with rituximab compared to standard immunochemoth...

Active, not recruiting
Relapsed Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Drug: Gemcitabine
Drug: Rituximab

Phase 3

ADC Therapeutics

Seville, Spain and 143 other locations

to describe the efficacy and safety of patients with mantle cell lymphoma (MCL) receiving acalabrutinib in combination with R-CHOP for the f...

Enrolling
Mantle-cell Lymphoma
Drug: Acalabrutinib monotherapy
Drug: Acalabrutinib combination with Rituximab

Phase 2

AstraZeneca
AstraZeneca

Seville, Spain and 21 other locations

2 cohorts to assess safety and efficacy of emavusertib in combination with ibrutinib in participants with R/R primary central nervous system lymphoma...

Enrolling
Refractory Primary Central Nervous System Lymphoma
Relapsed Primary Central Nervous System Lymphoma
Drug: Emavusertib
Drug: Ibrutinib

Phase 1, Phase 2

Curis

Sevilla, Spain and 42 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems